Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients

Autor:	Sylwia Czekalska, Monika Paluszewska, Sebastian Grosicki, Sebastian Giebel, Iwona Solarska, Slawomira Kyrcz-Krzemien, Aleksander B. Skotnicki, Malgorzata Jakobczyk, Karolina Karabin, Katarzyna Borg, Karolina Matiakowska, Marek Kielbinski, Anna Ejduk, Wiesław Wiktor Jędrzejczak, Malgorzata Calbecka, Krzysztof Warzocha, Jerzy Holowiecki, I. Florek, Justyna Gajkowska-Kulik, Marta Pawelczyk, Bozena Jazwiec, Jolanta Libura, Beata Piatkowska-Jakubas, Magdalena Zawada, Olga Haus, Kazimierz Kuliczkowski, Grażyna Gadomska, Agnieszka Wierzbowska, Marta Libura, Dariusz Kata
Jazyk:	angličtina
Rok vydání:	2016
Předmět:	Oncology medicine.medical_specialty Myeloid Daunorubicin Karyotype Immunology Pharmacology Biochemistry 03 medical and health sciences fluids and secretions 0302 clinical medicine Gene Duplication hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols Gene duplication medicine Humans Cladribine business.industry Cytarabine hemic and immune systems Cell Biology Hematology medicine.disease Leukemia Myeloid Acute Leukemia Treatment Outcome medicine.anatomical_structure fms-Like Tyrosine Kinase 3 030220 oncology & carcinogenesis embryonic structures Fms-Like Tyrosine Kinase 3 business psychological phenomena and processes 030215 immunology medicine.drug
Popis:	To the editor: Internal tandem duplication in the FLT3 gene ( FLT3- ITD) has been recognized as a marker conferring poor outcome in patients with normal karyotype acute myeloid leukemia (NK-AML).[1][1] Because of the inferior outcome of FLT3- ITD+ NK-AML patients when treated with standard
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c2cdba97bad8e63dd3d50ae39548812 https://ruj.uj.edu.pl/xmlui/handle/item/93427 Zobrazit plný text záznamu